Related Experiment Video
Updated: Mar 1, 2026
05:26
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
Published on: May 28, 2019
9.7K
Optimal Anticoagulant Therapy in ST Elevation Myocardial Infarction Interventions
Estefania Oliveros1, Sameer Mehta2, Ana Isabel Flores1
1Lumen Foundation, 55 Pinta Road, Miami, FL 33133, USA.
Interventional Cardiology Clinics
|June 6, 2017
Summary
Bivalirudin is recommended for ST-elevation myocardial infarction patients undergoing percutaneous coronary intervention. This direct thrombin inhibitor offers reduced bleeding and mortality compared to heparin plus glycoprotein IIb/IIIa inhibitors.
Area of Science:
- Cardiology
- Pharmacology
Background:
- ST-elevation myocardial infarction (STEMI) requires effective anticoagulant therapy.
- Percutaneous coronary intervention (PCI) is a primary treatment for STEMI.
Purpose of the Study:
- To evaluate bivalirudin as an anticoagulant in STEMI patients undergoing PCI.
- To compare bivalirudin with heparin plus glycoprotein IIb/IIIa inhibitors.
Main Methods:
- Direct thrombin inhibitor therapy with bivalirudin.
- Combination therapy with aspirin and P2Y12 inhibitors.
- Comparative analysis of anticoagulant strategies.
Main Results:
- Bivalirudin demonstrated efficacy and safety in managing coronary artery disease thrombus.
- Reduced severe bleeding and inpatient mortality were observed with bivalirudin.
- Lower overall costs were associated with bivalirudin use.
Conclusions:
- Bivalirudin is a safe and effective alternative for STEMI patients undergoing PCI.
- It offers advantages over traditional heparin and glycoprotein IIb/IIIa inhibitor combinations.
- Careful monitoring for late stent thrombosis with thienopyridines is advised.
Related Concept Videos
01:28Acute Coronary Syndrome IV: Interprofessional Care
347
IntroductionThe management of Acute Coronary Syndrome (ACS) aims to minimize myocardial damage, preserve myocardial function, and prevent complications.Initial ManagementInpatient management involves continuous cardiac monitoring, preferably in an ICU, focusing on blood pressure, serum sodium, potassium, and creatinine levels, and urine output. Ongoing pharmacologic management is crucial for stabilizing the patient.Supplemental Oxygen: Administer supplemental oxygen if oxygen saturation is...
347
01:30Acute Coronary Syndrome I: Introduction
1.3K
Acute Coronary Syndrome (ACS) encompasses a spectrum of heart conditions caused by sudden obstruction of coronary arteries, typically resulting from the rupture of an atherosclerotic plaque and subsequent thrombus (blood clot) formation. This obstruction can lead to partial or complete blockage of blood flow, causing varying degrees of myocardial ischemia or infarction.ACS includes the following clinical entities:Unstable Angina (UA)Non-ST-Elevation Myocardial Infarction (NSTEMI)ST-Elevation...
1.3K
01:29Venous Thrombosis III: Interprofessional Care
423
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
423
01:14Myocarditis III: Medical Management
266
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
266
01:30Anticoagulant Drugs: Low-Molecular-Weight Heparins
2.1K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.1K
01:27Coronary Artery Disease V: Interprofessional Care
346
Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
346